FUNDAMENTALS |
MarketCap: |
12 082 mill
|
EPS: |
9.22
|
P/E: |
25.52
|
Earnings Date: |
May 09, 2024 |
SharesOutstanding: |
51.35 mill
|
Avg Daily Volume: |
0.541 mill
|
RATING
2024-05-08 |
S-
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Neutral
|
|
Price To Book: |
Buy
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 2/23 | 3/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
1.65x
|
Company: PE 25.52 | sector: PE 15.43
|
PE RATIO: COMPANY / INDUSTRY |
0.23x
|
Company: PE 25.52 | industry: PE 109.92
|
DISCOUNTED CASH FLOW VALUE |
$155.19
(-34.04%)
$-80.10
|
Date: 2024-05-09
|
Expected Trading Range (DAY) |
$ 228.31 - 242.27
( +/- 2.97%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-05-02 | Pease Flavia | Sell | 893 | Common Stock |
2024-01-29 | Creamer Victoria L | Buy | 2 934 | Common Stock |
2024-01-29 | Creamer Victoria L | Sell | 924 | Common Stock |
2024-01-29 | Foster James C | Buy | 23 741 | Common Stock |
2024-01-29 | Foster James C | Sell | 10 540 | Common Stock |
INSIDER POWER |
-0.49
|
Last
100 transactions |
Buy:
164 068 | Sell:
161 687 |
Forecast:
16:00 - $235.29
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $235.29
Forecast 2: 16:00 - $235.29
Forecast 3: 16:00 - $235.29
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$235.29 (-0.43% )
|
Volume |
0.592 mill
|
Avg. Vol. |
0.541 mill
|
% of Avg. Vol |
109.43 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For CRL
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.